IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2

Romain Lévy; Paul Bastard; Fanny Lanternier; Marc Lecuit; Shen-Ying Zhang; Jean-Laurent Casanova

doi:10.1007/s10875-020-00933-0

IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2

J Clin Immunol. 2021 Jan;41(1):26-27. doi: 10.1007/s10875-020-00933-0. Epub 2021 Jan 3.

Authors

Romain Lévy^{1

2

3}, Paul Bastard^{4

5

6}, Fanny Lanternier^{5

7}, Marc Lecuit^{5

7

8}, Shen-Ying Zhang^{4

5

6}, Jean-Laurent Casanova^{4

5

6

9}

Affiliations

¹ Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France. romain.levy@inserm.fr.
² University of Paris, Imagine Institute, Paris, France. romain.levy@inserm.fr.
³ Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, AP-HP, Paris, France. romain.levy@inserm.fr.
⁴ Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
⁵ University of Paris, Imagine Institute, Paris, France.
⁶ St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
⁷ Necker Pasteur Center for Infectious Diseases and Tropical Medicine, Necker Hospital for Sick Children, AP-HP, Paris, France.
⁸ Biology of Infection Unit, Institut Pasteur, Inserm U1117, Paris, France.
⁹ Howard Hughes Medical Institute, New York, NY, 10065, USA.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
COVID-19 / diagnosis
COVID-19 / immunology
COVID-19 / virology
COVID-19 Drug Treatment*
Female
Humans
Interferon Regulatory Factor-3 / deficiency*
Interferon Regulatory Factor-3 / genetics
Interferon Type I / immunology
Interferon Type I / metabolism
Interferon-alpha / therapeutic use*
Polyethylene Glycols / therapeutic use*
Primary Immunodeficiency Diseases / complications
Primary Immunodeficiency Diseases / genetics
Primary Immunodeficiency Diseases / immunology*
Recombinant Proteins / therapeutic use
SARS-CoV-2 / immunology
SARS-CoV-2 / isolation & purification
Toll-Like Receptor 3 / deficiency*
Toll-Like Receptor 3 / genetics
Treatment Outcome

Substances

IRF3 protein, human
Interferon Regulatory Factor-3
Interferon Type I
Interferon-alpha
Recombinant Proteins
TLR3 protein, human
Toll-Like Receptor 3
Polyethylene Glycols
peginterferon alfa-2a

Publication types

MeSH terms

Substances

Grants and funding